Goldman Sachs Group Inc. Sells 156,917 Shares of Compass Therapeutics, Inc. $CMPX

Key Points

• Goldman Sachs Group Inc. reduced its stake in Compass Therapeutics by 40.2%, selling 156,917 shares, leaving it with approximately 233,522 shares worth $444,000.
• Several institutional investors, including SG Americas Securities LLC and Nuveen LLC, have recently increased or initiated positions in Compass Therapeutics, with a collective institutional ownership of 68.43%.
• Equities analysts have a consensus rating of "Buy" for Compass Therapeutics, with target prices ranging from $9.00 to $32.00, reflecting positive sentiment despite a recent earnings miss.

Goldman Sachs Group Inc. cut its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 40.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 233,522 shares of the company's stock after selling 156,917 shares during the quarter. Goldman Sachs Group Inc. owned about 0.17% of Compass Therapeutics worth $444,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of CMPX. SG Americas Securities LLC raised its stake in Compass Therapeutics by 138.2% in the first quarter. SG Americas Securities LLC now owns 940,784 shares of the company's stock worth $1,787,000 after buying an additional 545,767 shares in the last quarter. Nuveen LLC purchased a new position in shares of Compass Therapeutics in the 1st quarter valued at approximately $579,000. Propel Bio Management LLC purchased a new position in shares of Compass Therapeutics in the 1st quarter valued at approximately $434,000. Wellington Management Group LLP purchased a new position in shares of Compass Therapeutics in the 1st quarter valued at approximately $423,000. Finally, Deutsche Bank AG bought a new position in Compass Therapeutics in the first quarter worth $194,000. 68.43% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Guggenheim raised their target price on shares of Compass Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research note on Tuesday, August 12th. D. Boral Capital reaffirmed a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, August 12th. Finally, Raymond James Financial raised Compass Therapeutics to an "outperform" rating and set a $9.00 price objective for the company in a research report on Tuesday, July 1st. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, Compass Therapeutics currently has an average rating of "Buy" and a consensus target price of $13.88.

Compass Therapeutics Stock Up 7.2%

Shares of CMPX opened at $3.74 on Friday. The company has a market capitalization of $517.18 million, a P/E ratio of -8.31 and a beta of 1.50. The firm has a 50 day moving average of $3.23 and a 200 day moving average of $2.55. Compass Therapeutics, Inc. has a twelve month low of $1.27 and a twelve month high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). On average, sell-side analysts expect that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

Want to see what other hedge funds are holding CMPX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.